Clinical trials
Phase 2 Carcinoma, Hepatocellular trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
74 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 5 |
| 2012 | 5 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 7 |
| 2022 | 3 |
| 2023 | 9 |
| 2025 | 3 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 39 |
| Recruiting | 9 |
| Unknown status | 9 |
| Terminated | 7 |
| Active, not recruiting | 5 |
| Not yet recruiting | 4 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Seoul National University Hospital | 11 |
| Asan Medical Center | 8 |
| Bayer | 6 |
| Samsung Medical Center | 6 |
| Yonsei University | 4 |
| CHA University | 3 |
| Jennerex Biotherapeutics | 3 |
| Korea Cancer Center Hospital | 3 |
| Bristol-Myers Squibb | 2 |
| GC Cell Corporation | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Hepatocellular | 74 |
| Liver Neoplasms | 13 |
| Cholangiocarcinoma | 4 |
| Biliary Tract Neoplasms | 3 |
| Neoplasm Metastasis | 3 |
| Stomach Neoplasms | 3 |
| Esophageal Neoplasms | 2 |
| Gallbladder Neoplasms | 2 |
| Gastrointestinal Stromal Tumors | 2 |
| Neoplasms | 2 |
Trials
Showing 1 to 25 of 74. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.